Please login to the form below

The vicious circle of pharmaceutical tendering

Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.

Pharmaceutical tendering and contracting is now approximately a quarter of total global turnover, though this is just an estimate as the level of tendering is market- and product-dependent. The impact of tendering on pharmaceutical business, however, is mainly through price erosion.

Open tendering, which means all suppliers are invited to bid, results in the lowest prices, especially when many suppliers are interested in the contract. Other drivers of price erosion include high prices, high volumes, and tendering by ‘winner takes all’ where there are alternatives available.

The ‘winner takes all’ pricing game

We developed a pricing game where the participants are split into competitive teams that are bidding for the business of six hospitals. Each hospital is tendering for full volume in a ‘winner takes all’ market. The hospitals have different volume needs, incumbent player(s) at the start of the game and price sensitivity, and participants know or can imply these characteristics from the hospital descriptions. The game has pre-set award conditions, threshold to switch (if any), growth rates by customer, and ‘attractiveness’ to the customers.

To read the rest of this insightful article, please visit: https://www.validinsight.com/pharmaceutical-tendering-contracting/

18th May 2020

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

Valid Insight are hiring for Consultants in Value Communication (mid to senior levels)
New role available for Consultants in Value Communication with experience in market access writing and value communication.
Valid Insight
Webinar: Maintaining market access through a pandemic, 6 months on
In this webinar, Valid Insight explore market access and how it has evolved through a pandemic over the past 6 months.
Valid Insight
Webinar: How to develop an optimal value story for your product
This webinar is part of the ongoing expert insights series run by Valid Insight
Valid Insight
Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight